Kedudukan dalam Saham
#35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Harga Saham
$0.0327
Disegerakkan terakhir: 2025-06-17
Perubahan (1 tahun)
0.00%
Perdagangan Gamida Cell Ltd. (GMDA)
Harga GMDA dengan permodalan pasaran b
Modal pasaran bagi Gamida Cell Ltd.(GMDA)
Modal Pasaran: $4.34M
Sehingga August 2026, Gamida Cell Ltd. mempunyai modal pasaran sebanyak $4.34M. Ini menjadikan Gamida Cell Ltd. syarikat ke-35164th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Gamida Cell Ltd. dari 2018 hingga 2026
GMDA berbanding dengan 5 teratas yang paling popular stocks
| Harga GMDA |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.452T
|
+125,692,588.97%
|
|
|
|
|
$4.490T
|
+103,517,214.83%
|
|
|
|
|
$4.162T
|
+95,964,100.96%
|
|
|
|
|
$3.676T
|
+84,757,892.92%
|
|
|
|
|
$2.833T
|
+65,315,634.53%
|
